BOLT BIOTHERAPEUTICS INC
BOLTNASDAQTrading Snapshot
- Day Range
- $4.88 β $5.21
- 52-Week Range
- $3.10 β $7.78
- Volume (shares)
- 60,491
- Avg Volume (shares)
- β
- Shares Outstanding
- 2.6M
- Next Earnings
- 2027-03-11
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-16.44
- Dividend Yield
- β
- Dilution (1yr)
- β2.3%
BOLT BIOTHERAPEUTICS INC
BOLTAbout BOLT BIOTHERAPEUTICS INC
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt's primary development focus Initiated Phase 2 studies with PRA

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger β RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action AttorneyΒ Juan Monteverde with Monteverde & Associates PC (the βM&A Class Action Firmβ), has recovered millions of dollars for shareholders and is recognized as a

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
/PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for

Bolt Biotherapeutics to Participate in Upcoming Conferences
REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (βBoltβ or the βCompanyβ), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multis

Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Β (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top